Tony Hagen

September 05, 2021

For patients with diffuse large B-cell lymphoma (DLBCL), PET/CT scans conducted in the first cycle of salvage therapy can predict for response, according to a study.

August 29, 2021

A review of treatment options in diffuse large B-cell lymphoma (DLBCL) addresses common subtypes and patient response to standard of care.

July 29, 2021

The designation means that pharmacists can switch patients to the less-expensive version of insulin without seeking approval from the clinician.

June 13, 2021

Bispecific T-cell engagers and chimeric antigen receptor T-cell therapies seem destined to move into earlier lines of therapy for multiple myeloma (MM), speakers at the European Hematology Association 2021 Virtual Congress said.

June 12, 2021

Using limited data from the ASPEN trial, investigators estimated survival probability and cost-effectiveness for zanubrutinib vs other agents in Waldenström macroglobulinemia.

June 11, 2021

There are many unknowns for third-line chronic myeloid leukemia (CML) treatment and beyond, speakers said at the EHA2021 Virtual Congress.

April 22, 2021

For Alberta and Green Shield Canada, savings are beginning to add up from switching initiatives for multiple reference biologics.

April 20, 2021

Hidradenitis suppurativa (HS) is a difficult-to-treat skin condition that has responded to infliximab, although payer support in this setting is often lacking.

April 12, 2021

Hospital reimbursement deals slow the adoption of biosimilars in oncology, but cost concerns contribute to the incentives to use these agents.

August 17, 2020

The challenges of complying with payer mandates in biosimilars were discussed in a webinar sponsored by The American Journal of Managed Care® and The Center for Biosimilars®.